1
|
McAllister RM, Gardner MB, Nicolson MO, Gilden RV, Davidson N. RD-114 virus: characterization and identification. Prog Exp Tumor Res 2015; 21:196-215. [PMID: 77028 DOI: 10.1159/000400864] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
2
|
Gardner MB, Officer JE, Rongey RW, Charman HP, Hartley JW, Estes JD, Huebner RJ. C-type RNA tumor virus in wild house mice (Mus musculus). Bibl Haematol 2015; 39:335-44. [PMID: 4130397 DOI: 10.1159/000427860] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
3
|
Roy-Burman P, Pal BK, Kaplan MB, Wright M, Gardner MB. Biochemical properties of wild mouse oncornaviruses with lymphomagenic and neurotropic activities. Bibl Haematol 2015:627-37. [PMID: 169831 DOI: 10.1159/000397584] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The close immunologic relation between the group-specific and polymerase proteins of the wild mouse derived and the established strains of mouse type C oncornaviruses, and the lack of any unusual structural polypeptide or RNA components in the wild mouse virions, eliminate the possibility of detectable contamination by a class of virus different from the mouse oncornavirus class in the wild mouse virus preparations. Liquid hybridization studies with a wild mouse viral 70S 3H-RNA and cellular DNA under conditions of DNA excess, suggest that a significant fraction but not all of the virus-specific nucleotide sequences is present in all normal and tumored wild mouse tissues tested. These virus related sequences may possibly be attributed to a hypothetical endogenous inherited type C virus genome(s) carried by all wild mice or to an infection by one or more but not all of the different exogenous strains of wild mouse type C viruses which could possibly be present in the virus preparation used. The findings are consistent with wild mouse derived type C viruses being either entirely exogenous or a mixture of endogenous and exogenous viruses. This interpretation is also consistent with the earlier observation that certain wild mouse type C viruses are exogenously transmitted, transplacentally, and via milk. The possible relation of the virus heterogeneity or the distinct characteristics of the virus surface molecules to the diverse pathogenicity of the wild mouse oncornaviruses is discussed.
Collapse
|
4
|
McAllister RM, Isaacs H, Gardner MB, Klement V. Transplantation of human rhabdomyosarcoma cells in heterogous hosts: tumors formed and viruses recovered. Bibl Haematol 2015:659-62. [PMID: 1164405 DOI: 10.1159/000397588] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
5
|
Gardner MB, Baumgarth N, Fell A, McSorley SJ, Solnick JV, Bevins CL. Meeting report: a symposium on the evolution of common molecular pathways underlying innate immunity. Microbes Infect 2012; 14:667-71. [DOI: 10.1016/j.micinf.2012.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2012] [Accepted: 04/03/2012] [Indexed: 11/16/2022]
|
6
|
Marquez JP, Rivera R, Kang KH, Gardner MB, Torres JV. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression. Viral Immunol 2012; 25:141-52. [PMID: 22486305 DOI: 10.1089/vim.2011.0066] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Human papillomavirus (HPV) is associated with premalignant lesions such as high-grade cervical intraepithelial neoplasia (CIN-III) with potential progression to cervical carcinoma. There are now preventive vaccines against HPV. However, no effective therapeutic vaccine or immunological treatment exists for individuals already infected or for the 470,000 women that develop high-grade dysplasia, carcinoma in situ, and cervical cancer each year. More than half of these women die from cervical cancer. Relative non-immunogenicity of HPV infection is one of the main reasons for the difficulty in designing a comprehensive therapeutic vaccine against HPV-induced premalignant lesions and cervical carcinoma. HPV E6 and E7 proteins, the major HPV oncogenes, are highly immunogenic but fail to induce cross-reactive and protective immune responses against heterologous strains. We designed and synthesized a therapeutic peptide vaccine comprised of multivalent peptide mixtures called hypervariable epitope constructs (HECs) that represent the major epitope variants of the oncogenic E7 structural protein, and assessed their immunogenicity and in vivo efficacy in mice. Our results show that this peptide vaccine can induce strong, HPV-specific, T-helper cell and CTL responses. More significantly, we have demonstrated that the vaccine is efficacious as a therapeutic agent in a mouse HPV tumor model. Therefore, the HPV HEC vaccine approach described herein can potentially prevent progression of HPV-associated premalignant lesions, and may also be therapeutic against tumors associated with HPV.
Collapse
Affiliation(s)
- Juan P Marquez
- Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA
| | | | | | | | | |
Collapse
|
7
|
Gardner MB, Marthas ML. Introduction to abstracts of the 13th Annual Symposium on Nonhuman Primate Models for AIDS. J Med Primatol 2011. [DOI: 10.1111/j.1600-0684.1995.tb00162.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Kang KH, Yamamura Y, Carlos MP, Karvelas N, Kim IS, Sunkara D, Rivera R, Gardner MB, Anderson DE, Diaz-Mitoma F, Torres J, Marquez JP. Synthetic antigens representing the antigenic variation of human hepatitis C virus. Viral Immunol 2011; 23:497-508. [PMID: 20883164 DOI: 10.1089/vim.2010.0043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Immune responses against hepatitis C virus (HCV) have been studied by numerous groups. However, details concerning the production of antibodies to antigenically variable epitopes remain to be elucidated. Since the sequences of the variable regions of several HCV proteins are different among the virus strains infecting patients, we decided to design peptide combinations that represent the theoretical maximum antigenic variation of each epitope to be used as capture antigens. We prepared six peptide mixtures (hypervariable epitope constructs; HECs) representing six different epitopes from structural and non-structural proteins of HCV from genotypes 1-6. Plasma from 300 HCV patients was tested to determine if their antibodies recognize the synthetic constructs. All the patients were chronically infected with diverse HCV genotypes and did not receive antiviral treatment. Antibodies to one or more of the HECs were detected in all of the HCV-infected individuals. Immunogenicity of the HCV HECs was also evaluated in outbred and inbred mice. Strong HEC-specific antibodies were produced, and cellular responses were also induced that were Th-1 rather than Th-2. Our results show that HCV HECs are both antigens that can be used to detect the broad cross-reactivity of antibodies from HCV-infected patients, and strong immunogens that can induce antigen-specific humoral and cellular immune responses in mice.
Collapse
Affiliation(s)
- Kyung Hee Kang
- Department of Medical Microbiology and Immunology, School of Medicine, University of California-Davis, Davis, California 95616, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Sparger EE, Gardner MB, Barry PA. Exploiting the natural history of cytomegalovirus to vaccinate against HIV. Expert Rev Vaccines 2009; 8:993-7. [PMID: 19627183 DOI: 10.1586/erv.09.70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Ellen E Sparger
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
| | | | | |
Collapse
|
10
|
Abstract
Macaques have served as models for more than 70 human infectious diseases of diverse etiologies, including a multitude of agents—bacteria, viruses, fungi, parasites, prions. The remarkable diversity of human infectious diseases that have been modeled in the macaque includes global, childhood, and tropical diseases as well as newly emergent, sexually transmitted, oncogenic, degenerative neurologic, potential bioterrorism, and miscellaneous other diseases. Historically, macaques played a major role in establishing the etiology of yellow fever, polio, and prion diseases. With rare exceptions (Chagas disease, bartonellosis), all of the infectious diseases in this review are of Old World origin. Perhaps most surprising is the large number of tropical (16), newly emergent (7), and bioterrorism diseases (9) that have been modeled in macaques. Many of these human diseases (e.g., AIDS, hepatitis E, bartonellosis) are a consequence of zoonotic infection. However, infectious agents of certain diseases, including measles and tuberculosis, can sometimes go both ways, and thus several human pathogens are threats to nonhuman primates including macaques. Through experimental studies in macaques, researchers have gained insight into pathogenic mechanisms and novel treatment and vaccine approaches for many human infectious diseases, most notably acquired immunodeficiency syndrome (AIDS), which is caused by infection with human immunodeficiency virus (HIV). Other infectious agents for which macaques have been a uniquely valuable resource for biomedical research, and particularly vaccinology, include influenza virus, paramyxoviruses, flaviviruses, arenaviruses, hepatitis E virus, papillomavirus, smallpox virus, Mycobacteria, Bacillus anthracis, Helicobacter pylori, Yersinia pestis, and Plasmodium species. This review summarizes the extensive past and present research on macaque models of human infectious disease.
Collapse
Affiliation(s)
- Murray B Gardner
- Center for Comparative Medicine, University of California, Davis, CA 95616, USA.
| | | |
Collapse
|
11
|
Affiliation(s)
- Murray B Gardner
- Center for Comparative Medicine, University of California, Davis, CA 95616, USA.
| |
Collapse
|
12
|
Reyes RA, Canfield DR, Esser U, Adamson LA, Brown CR, Cheng-Mayer C, Gardner MB, Harouse JM, Luciw PA. Induction of simian AIDS in infant rhesus macaques infected with CCR5- or CXCR4-utilizing simian-human immunodeficiency viruses is associated with distinct lesions of the thymus. J Virol 2004; 78:2121-30. [PMID: 14747577 PMCID: PMC369416 DOI: 10.1128/jvi.78.4.2121-2130.2004] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Newborn rhesus macaques were infected with two chimeric simian-human immunodeficiency virus (SHIV) strains which contain unique human immunodeficiency virus type 1 (HIV-1) env genes and exhibit distinct phenotypes. Infection with either the CCR5-specific SHIV(SF162P3) or the CXCR4-utilizing SHIV(SF33A) resulted in clinical manifestations consistent with simian AIDS. Most prominent in this study was the detection of severe thymic involution in all SHIV(SF33A)-infected infants, which is very similar to HIV-1-induced thymic dysfunction in children who exhibit a rapid pattern of disease progression. In contrast, SHIV(SF162P3) induced only a minor disruption in thymic morphology. Consistent with the distribution of the coreceptors CXCR4 and CCR5 within the thymus, the expression of SHIV(SF162P3) was restricted to the thymic medulla, whereas SHIV(SF33A) was preferentially detected in the cortex. This dichotomy of tissue tropism is similar to the differential tropism of HIV-1 isolates observed in the reconstituted human thymus in SCID-hu mice. Accordingly, our results show that the SHIV-monkey model can be used for the molecular dissection of cell and tissue tropisms controlled by the HIV-1 env gene and for the analysis of mechanisms of viral immunopathogenesis in AIDS. Furthermore, these findings could help explain the rapid progression of disease observed in some HIV-1-infected children.
Collapse
Affiliation(s)
- R A Reyes
- Center for Comparative Medicine, University of California, Davis, California 95616, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
The author has had the unique opportunity to participate, over the last 35 years, in the retrovirus research field that proceeded and followed the discovery of human, simian and feline AIDS. The onset of human AIDS was certainly unanticipated, but in retrospect, the warning signs had been present for at least a decade in captive macaques. I will briefly summarize the key scientific knowledge and 'mindset' leading up to these events and will outline the major contributions and unanswered questions arising from the simian model of AIDS.
Collapse
Affiliation(s)
- M B Gardner
- Center for Comparative Medicine and California National Primate Research Center, Davis, CA 95616, USA.
| |
Collapse
|
14
|
Shacklett BL, Shaw KES, Adamson LA, Wilkens DT, Cox CA, Montefiori DC, Gardner MB, Sonigo P, Luciw PA. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J Virol 2002; 76:11365-78. [PMID: 12388697 PMCID: PMC136751 DOI: 10.1128/jvi.76.22.11365-11378.2002] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2002] [Accepted: 08/15/2002] [Indexed: 11/20/2022] Open
Abstract
Attenuated molecular clones of simian immunodeficiency virus (SIVmac) are important tools for studying the correlates of protective immunity to lentivirus infection in nonhuman primates. The most highly attenuated SIVmac mutants fail to induce disease but also fail to induce immune responses capable of protecting macaques from challenge with pathogenic virus. We recently described a novel attenuated virus, SIVmac-M4, containing multiple mutations in the transmembrane protein (TM) intracytoplasmic domain. This domain has been implicated in viral assembly, infectivity, and cytopathogenicity. Whereas parental SIVmac239-Nef(+) induced persistent viremia and simian AIDS in rhesus macaques, SIVmac-M4 induced transient viremia in juvenile and neonatal macaques, with no disease for at least 1 year postinfection. In this vaccine study, 8 macaques that were infected as juveniles (n = 4) or neonates (n = 4) with SIVmac-M4 were challenged with pathogenic SIVmac251 administered through oral mucosa. At 1 year postchallenge, six of the eight macaques had low to undetectable plasma viremia levels. Assays of cell-mediated immune responses to SIVmac Gag, Pol, Env, and Nef revealed that all animals developed strong CD8(+) T-cell responses to Gag after challenge but not before. Unvaccinated control animals challenged with SIVmac251 developed persistent viremia, had significantly weaker SIV-specific T-cell responses, and developed AIDS-related symptoms. These findings demonstrate that SIVmac-M4, which contains a full-length Nef coding region and multiple point mutations in the TM, can provide substantial protection from mucosal challenge with pathogenic SIVmac251.
Collapse
Affiliation(s)
- Barbara L Shacklett
- Gladstone Institute of Virology and Immunology, University of California-San Francisco, San Francisco 94141-9100, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Sequar G, Britt WJ, Lakeman FD, Lockridge KM, Tarara RP, Canfield DR, Zhou SS, Gardner MB, Barry PA. Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis. J Virol 2002; 76:7661-71. [PMID: 12097580 PMCID: PMC136401 DOI: 10.1128/jvi.76.15.7661-7671.2002] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Human cytomegalovirus (HCMV) possesses low pathogenic potential in an immunocompetent host. In the immunosuppressed host, however, a wide spectrum of infection outcomes, ranging from asymptomatic to life threatening, can follow either primary or nonprimary infection. The variability in the manifestations of HCMV infection in immunosuppressed individuals implies that there is a threshold of host antiviral immunity that can effectively limit disease potential. We used a nonhuman primate model of CMV infection to assess the relationship between CMV disease and the levels of developing anti-CMV immunity. Naive rhesus macaques were inoculated with rhesus cytomegalovirus (RhCMV) followed 2 or 11 weeks later by inoculation with pathogenic simian immunodeficiency virus SIVmac239. Two of four monkeys inoculated with SIV at 2 weeks after inoculation with RhCMV died within 11 weeks with simian AIDS (SAIDS), including activated RhCMV infection. Neither animal had detectable anti-SIV antibodies. The other two animals died 17 and 27 weeks after SIV inoculation with either SAIDS or early lymphoid depletion, although no histological evidence of activated RhCMV was observed. Both had weak anti-SIV antibody titers. RhCMV antibody responses for this group of monkeys were significantly below those of control animals inoculated with only RhCMV. In addition, all animals of this group had persistent RhCMV DNA in plasma and high copy numbers of RhCMV in tissues. In contrast, animals that were inoculated with SIV at 11 weeks after RhCMV infection rarely exhibited RhCMV DNA in plasma, had low copy numbers of RhCMV DNA in most tissues, and did not develop early onset of SAIDS or activated RhCMV. SIV antibody titers were mostly robust and sustained in these monkeys. SIV inoculation blunted further development of RhCMV humoral responses, unlike the normal pattern of development in control monkeys following RhCMV inoculation. Anti-RhCMV immunoglobulin G levels and avidity were slightly below control values, but levels maintained were higher than those observed following SIV infection at 2 weeks after RhCMV inoculation. These findings demonstrate that SIV produces long-lasting insults to the humoral immune system beginning very early after SIV infection. The results also indicate that anti-RhCMV immune development at 11 weeks after infection was sufficient to protect the host from acute RhCMV sequelae following SIV infection, in contrast to the lack of protection afforded by only 2 weeks of immune response to RhCMV. As previously observed, monkeys that were not able to mount a significant immune response to SIV were the most susceptible to SAIDS, including activated RhCMV infection. Rapid development of SAIDS in animals inoculated with SIV 2 weeks after RhCMV inoculation suggests that RhCMV can augment SIV pathogenesis, particularly during primary infection by both viruses.
Collapse
Affiliation(s)
- Getachew Sequar
- Center for Comparative Medicine, University of California, Davis, California 95616, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Cardiff RD, Bern HA, Faulkin LJ, Daniel CW, Smith GH, Young LJT, Medina D, Gardner MB, Wellings SR, Shyamala G, Guzman RC, Rajkumar L, Yang J, Thordarson G, Nandi S, MacLeod CL, Oshima RG, Man AK, Sawai ET, Gregg JP, Cheung ATW, Lau DH. Contributions of mouse biology to breast cancer research. Comp Med 2002; 52:12-31. [PMID: 11900409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
17
|
Shacklett BL, Weber CJ, Shaw KE, Keddie EM, Gardner MB, Sonigo P, Luciw PA. The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques. J Virol 2000; 74:5836-44. [PMID: 10846063 PMCID: PMC112078 DOI: 10.1128/jvi.74.13.5836-5844.2000] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/1999] [Accepted: 03/31/2000] [Indexed: 11/20/2022] Open
Abstract
The human and simian immunodeficiency virus (HIV-1 and SIVmac) transmembrane proteins contain unusually long intracytoplasmic domains (ICD-TM). These domains are suggested to play a role in envelope fusogenicity, interaction with the viral matrix protein during assembly, viral infectivity, binding of intracellular calmodulin, disruption of membranes, and induction of apoptosis. Here we describe a novel mutant virus, SIVmac-M4, containing multiple mutations in the coding region for the ICD-TM of pathogenic molecular clone SIVmac239. Parental SIVmac239-Nef+ produces high-level persistent viremia and simian AIDS in both juvenile and newborn rhesus macaques. The ICD-TM region of SIVmac-M4 contains three stop codons, a +1 frameshift, and mutation of three highly conserved, charged residues in the conserved C-terminal alpha-helix referred to as lentivirus lytic peptide 1 (LLP-1). Overlapping reading frames for tat, rev, and nef are not affected by these changes. In this study, four juvenile macaques received SIVmac-M4 by intravenous injection. Plasma viremia, as measured by branched-DNA (bDNA) assay, reached a peak at 2 weeks postinoculation but dropped to below detectable levels by 12 weeks. At over 1.5 years postinoculation, all four juvenile macaques remain healthy and asymptomatic. In a subsequent experiment, four neonatal rhesus macaques were given SIVmac-M4 intravenously. These animals exhibited high levels of viremia in the acute phase (2 weeks postinoculation) but are showing a relatively low viral load in the chronic phase of infection, with no clinical signs of disease for 1 year. These findings demonstrated that the intracytoplasmic domain of the transmembrane Env (Env-TM) is a locus for attenuation in rhesus macaques.
Collapse
Affiliation(s)
- B L Shacklett
- Aaron Diamond AIDS Research Center, New York, NY, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:6087-95. [PMID: 10846092 PMCID: PMC112107 DOI: 10.1128/jvi.74.13.6087-6095.2000] [Citation(s) in RCA: 417] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2000] [Accepted: 03/31/2000] [Indexed: 12/20/2022] Open
Abstract
Despite recent insights into mucosal human immunodeficiency virus (HIV) transmission, the route used by primate lentiviruses to traverse the stratified squamous epithelium of mucosal surfaces remains undefined. To determine if dendritic cells (DC) are used by primate lentiviruses to traverse the epithelial barrier of the genital tract, rhesus macaques were intravaginally exposed to cell-free simian immunodeficiency virus SIVmac251. We examined formalin-fixed tissues and HLA-DR(+)-enriched cell suspensions to identify the cells containing SIV RNA in the genital tract and draining lymph nodes within the first 24 h of infection. Using SIV-specific fluorescent in situ hybridization combined with immunofluorescent antibody labeling of lineage-specific cell markers, numerous SIV RNA(+) DC were documented in cell suspensions from the vaginal epithelium 18 h after vaginal inoculation. In addition, we determined the minimum time that the SIV inoculum must remain in contact with the genital mucosa for the virus to move from the vaginal lumen into the mucosa. We now show that SIV enters the vaginal mucosa within 60 min of intravaginal exposure, infecting primarily intraepithelial DC and that SIV-infected cells are located in draining lymph nodes within 18 h of intravaginal SIV exposure. The speed with which primate lentiviruses penetrate mucosal surfaces, infect DC, and disseminate to draining lymph nodes poses a serious challenge to HIV vaccine development.
Collapse
Affiliation(s)
- J Hu
- California Regional Primate Research Center, School of Medicine, University of California, Davis 95616, USA
| | | | | |
Collapse
|
19
|
Leung NJ, Aldovini A, Young R, Jarvis MA, Smith JM, Meyer D, Anderson DE, Carlos MP, Gardner MB, Torres JV. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Virology 2000; 268:94-103. [PMID: 10683331 DOI: 10.1006/viro.1999.0131] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guérin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/blood
- BCG Vaccine/genetics
- BCG Vaccine/immunology
- Blotting, Western
- Cloning, Molecular
- Cytotoxicity, Immunologic
- Gene Products, env/genetics
- Gene Products, env/immunology
- Gene Products, env/metabolism
- Gene Products, gag/genetics
- Gene Products, gag/immunology
- Gene Products, gag/metabolism
- Gene Products, nef/genetics
- Gene Products, nef/immunology
- Gene Products, nef/metabolism
- Gene Products, pol/genetics
- Gene Products, pol/immunology
- Gene Products, pol/metabolism
- Immunoglobulin A/blood
- Immunoglobulin G/blood
- Lymphocyte Activation
- Macaca mulatta
- SAIDS Vaccines/genetics
- SAIDS Vaccines/immunology
- Simian Acquired Immunodeficiency Syndrome/prevention & control
- Simian Immunodeficiency Virus/genetics
- Simian Immunodeficiency Virus/immunology
- Simian Immunodeficiency Virus/metabolism
- T-Lymphocytes, Cytotoxic/immunology
- Vaccination
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- Viral Proteins/genetics
- Viral Proteins/immunology
- Viral Proteins/metabolism
Collapse
Affiliation(s)
- N J Leung
- Department of Medical Microbiology, School of Medicine, University of California, Davis, California, 95616, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Carlos MP, Anderson DE, Gardner MB, Torres JV. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein. AIDS Res Hum Retroviruses 2000; 16:153-61. [PMID: 10659054 DOI: 10.1089/088922200309494] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
Abstract
Variability of the major antigenic sites of the envelope glycoprotein of HIV-1 constitutes a major problem in the formulation of effective vaccines. We have prepared a synthetic peptide vaccine that represents the major hypervariable epitopes (V1 through V5) of the clade B HIV-1 envelope glycoprotein (gp120). We refer to this preparation as variable epitope immunogen or VEI vaccine. This construct takes into consideration the type and frequency of amino acid substitutions found at each epitope during the evolution of the virus in individual patients and in the target population. Immunization of mice, rabbits, and rhesus macaques with the VEI vaccine resulted in the induction of long-lasting, high-titered HIV-1 antibodies, including antibodies that neutralize primary isolates. We also documented lymphocyte proliferative responses to the VEI vaccine, its individual components, analogs, and subtype-specific peptides representing the major hypervariable regions of HIV-1 gp120. Delayed-type hypersensitivity responses to these antigens were also demonstrated in mice. Our results show that this vaccine is highly immunogenic and safe in animals. Our data suggest that this formulation could become an important component of combination vaccine approaches against HIV-1 and other antigenically variable pathogens.
Collapse
Affiliation(s)
- M P Carlos
- Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis 95616, USA
| | | | | | | |
Collapse
|
21
|
Meyer D, Anderson DE, Gardner MB, Torres JV. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques. AIDS Res Hum Retroviruses 1998; 14:751-60. [PMID: 9643375 DOI: 10.1089/aid.1998.14.751] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Using synthetic peptides, we developed an approach to account for protein epitope variability. We have prepared, in a single synthesis, a cocktail of peptides we have designated a hypervariable epitope construct (HEC), which collectively represents much of the in vivo variability seen in an epitope. Eight HECs representing the in vivo variability seen throughout the envelope glycoprotein of the simian immunodeficiency virus (SIV) were designed and synthesized. The constructs were collectively conjugated to KLH (HEC-KLH) or recombinant gp130 (HEC-rgp130) and used to immunize rabbits and rhesus macaques, respectively. Using sera collected from rabbits immunized with HEC-KLH, we demonstrated that individual components of the immunogen were recognized as antigen in ELISAs, and that the induced antibodies cross-reacted with several strains of SIV as well as with a strain of HIV-2. Following immunization of macaques with HEC-rgp130 antiviral antibodies were induced. These antibodies were still present 9.5 months after the last boost and were also capable of recognizing several different strains of SIV, including SIVmac239, SIVmac251, and SIVsmH3, as well as a strain of HIV-2 (HIV-2ROD). In addition, the antibodies were also capable of neutralizing SIV viral infectivity in vitro. Peripheral blood lymphocytes (PBLs) from immunized macaques proliferated in response to whole proteins and virus. Finally, sera from monkeys immunized with SIV, rgp130, and HIV-2 as well as sera from HIV-2-positive humans recognized HECs in ELISAs, demonstrating the relevance of these epitopes in vivo. This approach can be used as an effective method for generating a strong, broadly cross-reactive humoral response against HIV and can serve as an important component of combination vaccines against HIV and AIDS.
Collapse
Affiliation(s)
- D Meyer
- Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, 95616, USA
| | | | | | | |
Collapse
|
22
|
Gardner MB, Holden MK, Leikauskas JM, Richard RL. Partial body weight support with treadmill locomotion to improve gait after incomplete spinal cord injury: a single-subject experimental design. Phys Ther 1998; 78:361-74. [PMID: 9555919 DOI: 10.1093/ptj/78.4.361] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND AND PURPOSE Gait training with partial body weight support has been used to improve gait. In this study, changes in gait relative to speed, cadence, stride length, and percentages of stance and swing for both lower extremities (LEs) during comfortable walking, fast walking, and running were studied in a subject with an incomplete C-5 on C-6 spinal cord injury. SUBJECT AND METHODS A single-subject experimental design was used. Following a 6-week period of baseline measurements taken at various intervals (phase AI), the subject ambulated on a treadmill three times a week for 6 weeks with 32% of his body weight supported (phase B). Phase B was followed by a 3-week period without treatment during which measurements were taken at various intervals (phase AII). Gait variables were measured once a week during comfortable walking, fast walking, and running. Heart rate was monitored during treadmill training. RESULTS During comfortable walking, fast walking, and running, improvements were seen in gait speed. During running, improvements also were seen in stride length and percentages of stance and swing for the right LE. The largest changes were recorded during running. Smaller changes were recorded during comfortable walking and fast walking. CONCLUSION AND DISCUSSION These results justify testing the efficacy of this technique with larger groups of subjects with neurological impairments.
Collapse
Affiliation(s)
- M B Gardner
- MGH Institute of Health Professions, Boston, Mass, USA.
| | | | | | | |
Collapse
|
23
|
Abstract
Retrospective data indicate that two separate outbreaks of simian AIDS and associated lymphoma were caused by Simian Immunodeficiency Virus (SIVmac and SIVstm, respectively) in group-housed macaques at the California Regional Primate Research Center (CRPRC) in the early and mid-1970s. Because these epizootics were not then recognized as infectious in nature, surviving healthy SIV carriers were sent to other primate centers where they transmitted the viruses to resident macaques. The source of SIV at the CRPRC was by contact with co-housed seropositive sooty mangabeys. Spread of SIV via saliva and blood while fighting most likely accounted for these epizootics. Separate outbreaks of a somewhat different version of simian AIDS, caused by the simian Type D retrovirus (SRV-1), and spread from healthy carriers via saliva and blood also occurred in the late 1970s and early 1980s in group-housed macaques at the CRPRC. Initially, these SRV-1 outbreaks were also not recognized as infectious.
Collapse
Affiliation(s)
- M B Gardner
- University of California, School of Medicine, Department of Medical Pathology, Davis 95616, USA
| |
Collapse
|
24
|
Gardner MB, Luciw PA, Sawai ET, Marthas ML, Miller CJ, McChesney MB, Lerche NW, Pedersen NC. Simian retrovirus vaccines: simian retrovirus and simian immunodeficiency lentivirus. AIDS Res Hum Retroviruses 1996; 12:399-401. [PMID: 8882318 DOI: 10.1089/aid.1996.12.399] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Affiliation(s)
- M B Gardner
- Department of Medical Pathology, University of California at Davis 95616, USA
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Mansfield KG, Lerch NW, Gardner MB, Lackner AA. Origins of simian immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol 1995; 24:116-22. [PMID: 8751050 DOI: 10.1111/j.1600-0684.1995.tb00156.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A cohort of rhesus macaques (Macaca mulatta), obtained from the California Regional Primate Research Center (CRPRC) and necropsied in 1970-72 with lesions suggestive of simian immunodeficiency virus (SIV) infection, was identified at the New England Regional Primate Research Center (NERPRC). Polymerase chain reaction (PCR), DNA sequence analysis, and in situ hybridization were used to confirm the presence of SIV nucleic acids. This represents the earliest case of SIV infection at the NERPRC and suggests a common source for present day SIV isolates.
Collapse
Affiliation(s)
- K G Mansfield
- Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, 01772, USA
| | | | | | | |
Collapse
|
26
|
Mitchell WM, Torres J, Johnson PR, Hirsch V, Yilma T, Gardner MB, Robinson WE. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. AIDS 1995; 9:27-34. [PMID: 7893438 DOI: 10.1097/00002030-199501000-00004] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
OBJECTIVE To demonstrate that antibodies against amino acids (aa) 603-622 of the SIV gp41 transmembrane glycoprotein enhance infection of SIV in vivo. DESIGN A synthetic peptide derived from aa 603-622 of SIVmac251 gp41 was synthesized and tested for immunogenicity in rabbits and SIV-infected rhesus macaques. Next, SIV-naive animals were immunized with either a recombinant vaccinia virus expressing the SIV gp160 envelope glycoprotein (VVrgp160) and boosted three times with aa 603-622 (group 1, four animals), wild-type vaccinia virus and boosted with aa 603-622 (group 2, two animals), or VVrgp160 followed by three doses of an irrelevant peptide (group 3, two animals). Animals were challenged with SIVmac251. RESULTS Peptide aa 603-622 was immunogenic in rabbits. SIV-infected rhesus monkeys immunized with the peptide developed two-three log increases in antibodies to this peptide and antibodies that could enhance SIV infection in vitro. SIV-naive rhesus macaques in group 1 had higher levels of antibody to the peptide by enzyme-linked immunosorbent assay and higher levels of enhancing antibodies at the time of SIV challenge than the animals in groups 2 or 3. Following challenge with SIVmac251 the group 1 animals had detectable p27 antigen longer than animals in group 2 and 3 and died of simian AIDS before the respective animals in the two control groups (P < 0.05 by log-rank test). CONCLUSIONS aa 603-622 of SIV gp41, like aa 579-613 of HIV gp41, can stimulate production of antibodies that enhance SIV and HIV infection in vitro. Furthermore, immunization with this peptide suppressed beneficial effects of a gp160 vaccine and appeared to enhance SIV infection in vivo.
Collapse
Affiliation(s)
- W M Mitchell
- Department of Pathology, Vanderbilt University, Nashville, Tennessee
| | | | | | | | | | | | | |
Collapse
|
27
|
Gardner MB, Dandekar S. Neurobiology of simian and feline immunodeficiency virus infections. Curr Top Microbiol Immunol 1995; 202:135-50. [PMID: 7587360 DOI: 10.1007/978-3-642-79657-9_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- M B Gardner
- Department of Pathology, School of Medicine, University of California, Davis, USA
| | | |
Collapse
|
28
|
Affiliation(s)
- M B Gardner
- Department of Pathology, School of Medicine, University of California, Davis 95616
| | | |
Collapse
|
29
|
Abstract
Epitope variability is one of the greatest obstacles to development of synthetic peptide vaccines. Based on a recently described hypervariable epitope (aa 414-434) on the envelope glycoprotein (gp130) to simian immunodeficiency virus (SIVmac142), we have developed a novel approach to account for epitope variability. We have prepared, in a single synthesis, a cocktail of peptides, designated a hypervariable epitope construct (HEC), which collectively represent all the in vivo variability seen in an epitope. The HEC represents permutations of amino acid substitutions found in the epitope and has been able to induce antibodies with enhanced binding to native SIV and broad immunoreactivity to related epitope analogues.
Collapse
Affiliation(s)
- D E Anderson
- Department of Microbiology and Immunology, School of Medicine, University of California, Davis 95616
| | | | | | | | | |
Collapse
|
30
|
Gardner MB. The Virus Cancer Program of the 1970s: a personal and retrospective view. Lab Anim Sci 1994; 44:101-13. [PMID: 8028270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- M B Gardner
- Department of Pathology, School of Medicine, University of California, Davis 95616
| |
Collapse
|
31
|
Ahmad S, Lohman B, Marthas M, Giavedoni L, el-Amad Z, Haigwood NL, Scandella CJ, Gardner MB, Luciw PA, Yilma T. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses 1994; 10:195-204. [PMID: 8198872 DOI: 10.1089/aid.1994.10.195] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
As a safe alternative to inactivated and live-attenuated whole-virus SIV vaccines, we have evaluated the potential of SIVmac239 gp160 expressed by recombinant vaccinia virus (vSIVgp160) and baculovirus (bSIVgp160) to protectively immunize rhesus macaques against intravenous (i.v.) infection with pathogenic SIVmac isolates. Macaques were immunized with live vSIVgp160 and/or bSIVgp160 protein partially purified from insect cells. The challenge viruses, propagated in rhesus peripheral blood mononuclear cells, consisted of the molecular clone SIVmac239 and another genetically similar, uncloned isolate, SIVmac251. Although antibodies that bind gp130 were induced in all animals following immunization with SIVgp160, neutralizing antibodies were undetectable 1 week prior to virus challenge. These results differ from those for macaques vaccinated with inactivated, whole SIV. All animals became infected after i.v. inoculation with 1-10 AID50 of either challenge virus. For animals challenged with SIVmac251, but not those challenged with SIVmac239, the cell-free infectious virus load in plasma of vSIVgp160-primed, bSIVgp160-boosted macaques was significantly lower than in unimmunized controls at 2 weeks postchallenge. Virus virulence, immunization regimen, and challenge with homologous or heterologous virus are factors critical to the outcome of the study. Immunization with surface glycoprotein may not necessarily provide protective immunity against infection but may reduce virus load. The relationship between reduction in virus load by vaccination and delay in onset of disease remains to be determined.
Collapse
Affiliation(s)
- S Ahmad
- Department of Pathology, Microbiology, and Immunology, University of California at Davis 95616
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Passive immunization with plasma from an inactivated-whole SIVmac vaccine protected monkey conferred complete or partial protection to rhesus macaques challenged intravenously 4 or 18 hours later with 10 AID50 of homologous cell-free virus. In contrast, passive immunization with inactivated plasma or purified immunoglobulin (Ig) from SIVmac infected asymptomatic monkeys failed to protect any recipients similarly challenged and may have enhanced infection and accelerated disease. Administered 24 hours post challenge, anti-SIV Ig may also have enhanced the infection.
Collapse
|
33
|
Affiliation(s)
- M B Gardner
- Department of Pathology, School of Medicine, University of California, Davis 95616
| |
Collapse
|
34
|
Yasutomi Y, Palker TJ, Gardner MB, Haynes BF, Letvin NL. Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993; 151:5096-105. [PMID: 7691965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In view of the importance of cell-associated virus in AIDS virus transmission, an HIV vaccine should be able to induce a virus-specific CTL response. Traditional subunit vaccines have not elicited virus-specific CD8+ MHC class I-restricted CTL. We have used the simian immunodeficiency virus of macaques (SIVmac)/rhesus monkey model to explore the use of CTL epitope peptide-helper peptide conjugates for the vaccine elicitation of AIDS virus-specific CTL. We found that both the CTL epitope peptide-helper peptide conjugate and the CTL epitope peptide alone, when delivered in an emulsion with IFA, induced CTL epitope-specific CD8+ MHC class I-restricted CTL. These effector cells recognized processed viral protein and were readily cloned from PBL of the immunized monkeys. Moreover, the cloned effector cells inhibited SIVmac replication in PBL. Immunization with the CTL epitope peptide used in this study also elicited a CD4+ PBL proliferative response, suggesting that the peptide also contained a helper epitope. These studies provide further evidence for the potential usefulness of peptide-based AIDS virus vaccines.
Collapse
Affiliation(s)
- Y Yasutomi
- Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772
| | | | | | | | | |
Collapse
|
35
|
Yasutomi Y, Palker TJ, Gardner MB, Haynes BF, Letvin NL. Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. The Journal of Immunology 1993. [DOI: 10.4049/jimmunol.151.9.5096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
In view of the importance of cell-associated virus in AIDS virus transmission, an HIV vaccine should be able to induce a virus-specific CTL response. Traditional subunit vaccines have not elicited virus-specific CD8+ MHC class I-restricted CTL. We have used the simian immunodeficiency virus of macaques (SIVmac)/rhesus monkey model to explore the use of CTL epitope peptide-helper peptide conjugates for the vaccine elicitation of AIDS virus-specific CTL. We found that both the CTL epitope peptide-helper peptide conjugate and the CTL epitope peptide alone, when delivered in an emulsion with IFA, induced CTL epitope-specific CD8+ MHC class I-restricted CTL. These effector cells recognized processed viral protein and were readily cloned from PBL of the immunized monkeys. Moreover, the cloned effector cells inhibited SIVmac replication in PBL. Immunization with the CTL epitope peptide used in this study also elicited a CD4+ PBL proliferative response, suggesting that the peptide also contained a helper epitope. These studies provide further evidence for the potential usefulness of peptide-based AIDS virus vaccines.
Collapse
Affiliation(s)
- Y Yasutomi
- Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772
| | - T J Palker
- Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772
| | - M B Gardner
- Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772
| | - B F Haynes
- Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772
| | - N L Letvin
- Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772
| |
Collapse
|
36
|
Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J Immunol 1993; 151:1646-53. [PMID: 8335949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
We have tested synthetic peptides composed of Th (T1) and V3 loop B cell neutralizing determinants [SP10 MN(A)] of HIVMN gp120 and the fusogenic (F) domain of gp41 as immunogens in rhesus monkeys. After two immunizations with either HIV env peptide T1-SP10 MN(A) or F-T1-SP10 MN(A), rhesus monkey serum neutralization titers against the HIVMN isolate ranged from 1:160 to 1:1400, and in cell-cell syncytium inhibition assay ranged from 1:20 to 1:80. However, in contrast to animals immunized with T1-SP10 MN(A), animals immunized twice with F-T1-SP10 MN(A) had no rise in anti-gp120 and neutralizing antibodies with an additional immunization with F-T1-SP10 MN(A) peptide. One of 4 rhesus monkeys (18987) had anti-HIVMN antibodies that cross-neutralized divergent HIV isolates HIVIIIB and HIVRF. Serum from animal 18987 neutralized 5 of 10 HIV isolates tested, and neutralizing activity against HIVIIIB of 18987 serum was absorbed with the conserved gp120 loop V3 sequence IGPGRAF. Anti-HIV neutralizing antibodies were boosted after a 6-mo rest by 500 micrograms of T1-SP10 MN(A) in 4 of 4 animals previously immunized with T1-SP10 MN(A) and in 2 of 2 animals previously immunized with F-T1-SP10 MN(A). However, immunization after 6-mo rest of animal 18987 with 500 micrograms of T1-SP10 MN(A) peptide, although boosting anti-HIVMN neutralizing antibodies, selectively did not boost cross-neutralizing anti-HIVIIIB antibodies. Thus, synthetic peptides containing T and B cell epitopes of HIV gp120 can induce high levels of anti-HIVMN neutralizing antibodies in primates.
Collapse
Affiliation(s)
- B F Haynes
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. The Journal of Immunology 1993. [DOI: 10.4049/jimmunol.151.3.1646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
We have tested synthetic peptides composed of Th (T1) and V3 loop B cell neutralizing determinants [SP10 MN(A)] of HIVMN gp120 and the fusogenic (F) domain of gp41 as immunogens in rhesus monkeys. After two immunizations with either HIV env peptide T1-SP10 MN(A) or F-T1-SP10 MN(A), rhesus monkey serum neutralization titers against the HIVMN isolate ranged from 1:160 to 1:1400, and in cell-cell syncytium inhibition assay ranged from 1:20 to 1:80. However, in contrast to animals immunized with T1-SP10 MN(A), animals immunized twice with F-T1-SP10 MN(A) had no rise in anti-gp120 and neutralizing antibodies with an additional immunization with F-T1-SP10 MN(A) peptide. One of 4 rhesus monkeys (18987) had anti-HIVMN antibodies that cross-neutralized divergent HIV isolates HIVIIIB and HIVRF. Serum from animal 18987 neutralized 5 of 10 HIV isolates tested, and neutralizing activity against HIVIIIB of 18987 serum was absorbed with the conserved gp120 loop V3 sequence IGPGRAF. Anti-HIV neutralizing antibodies were boosted after a 6-mo rest by 500 micrograms of T1-SP10 MN(A) in 4 of 4 animals previously immunized with T1-SP10 MN(A) and in 2 of 2 animals previously immunized with F-T1-SP10 MN(A). However, immunization after 6-mo rest of animal 18987 with 500 micrograms of T1-SP10 MN(A) peptide, although boosting anti-HIVMN neutralizing antibodies, selectively did not boost cross-neutralizing anti-HIVIIIB antibodies. Thus, synthetic peptides containing T and B cell epitopes of HIV gp120 can induce high levels of anti-HIVMN neutralizing antibodies in primates.
Collapse
Affiliation(s)
- B F Haynes
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - J V Torres
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - A J Langlois
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - D P Bolognesi
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - M B Gardner
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - T J Palker
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - R M Scearce
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - D M Jones
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - M A Moody
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| | - C McDanal
- Department of Medicine, Duke University Arthritis Center, Durham, NC
| |
Collapse
|
38
|
Torres JV, Malley A, Banapour B, Anderson DE, Axthelm MK, Gardner MB, Benjamini E. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation. AIDS Res Hum Retroviruses 1993; 9:423-30. [PMID: 7686386 DOI: 10.1089/aid.1993.9.423] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
SIVmac infection of macaques is an important animal model for HIV infection and AIDS; this model is being utilized for development of antiviral therapies and vaccines. In the present article, we sought to identify neutralization epitopes of SIVmac envelope surface glycoprotein (gp130). Algorithms were used to predict antigenicity of specific regions. Four regions from the primary amino acid sequence of the viral surface glycoprotein were selected. A synthetic peptide representing one of these regions (414-434) induced virus-neutralizing antibodies in mice; in addition, this peptide induced T cell-proliferative responses in macaques. To address the in vivo relevance of these observations, we demonstrated that experimentally infected macaques produce antibodies to the neutralization epitope. In addition, rhesus macaques protected against infection by an inactivated SIV vaccine develop antibodies that bind to peptide 414-434. These observations demonstrate that the region that includes the sequence 414-434 in the fourth variable domain (V4) of SIVmac gp130 contains both a linear neutralization epitope and a T cell epitope.
Collapse
Affiliation(s)
- J V Torres
- Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis 95616
| | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
All six cats passively immunized with sera from either feline immunodeficiency virus (FIV)-vaccinated cats or cats infected with FIV (Petaluma strain) were protected from homologous FIV infection at a challenge dose that infected all six control cats. Passive immunization with sera from cats vaccinated with uninfected allogeneic T cells used to grow the vaccine virus did not protect either of two cats against the same FIV challenge. These results suggest that antiviral humoral immunity, perhaps in synergy with anticellular antibodies, may be responsible for previously reported vaccine protection.
Collapse
Affiliation(s)
- T Hohdatsu
- Department of Medicine, School of Veterinary Medicine, University of California, Davis 95616
| | | | | | | | | | | |
Collapse
|
40
|
Gardner MB. Acquired immunodeficiency syndrome vaccines. West J Med 1993; 158:296-7. [PMID: 8460513 PMCID: PMC1311758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
41
|
Affiliation(s)
- Murray B. Gardner
- Department of PathologySchool of MedicineCalifornia Regional Primate CenterUniversity of CaliforniaDavisU.S.A
| |
Collapse
|
42
|
Gardner MB. The importance of nonhuman primate research in the battle against AIDS: a historical perspective. J Med Primatol 1993; 22:86-91. [PMID: 8411112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- M B Gardner
- Department of Pathology, School of Medicine, University of California, Davis 95616
| |
Collapse
|
43
|
Torres JV, Anderson DE, Malley A, Banapour B, Axthelm MK, Benjamini E, Gardner MB. SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques. J Med Primatol 1993; 22:129-37. [PMID: 7692056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We analyzed SIV-specific monkey sera to localize B-cell epitopes of the envelope glycoprotein of SIV (gp130), using overlapping synthetic peptides representing the entire SIV gp130 protein and sera from experimentally infected monkeys and monkeys immunized with whole, inactivated SIV. A B-cell epitope which induces neutralizing antibody production and T-cell responses was characterized as well as a new B-cell epitope and a previously described neutralizing epitopes. Vaccinated monkey sera recognize the three epitopes differentially relative to unimmunized controls, and a correlation appears to exist between degree of cross-neutralization by infected monkey sera and degree of binding to these three regions.
Collapse
Affiliation(s)
- J V Torres
- Department of Microbiology and Immunology, School of Medicine, University of California, Davis 95616
| | | | | | | | | | | | | |
Collapse
|
44
|
Miller CJ, McGhee JR, Gardner MB. Mucosal immunity, HIV transmission, and AIDS. J Transl Med 1993; 68:129-45. [PMID: 8441249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Affiliation(s)
- C J Miller
- California Regional Primate Research Center, School of Veterinary Medicine, University of California, Davis
| | | | | |
Collapse
|
45
|
Torres JV, Anderson DE, Malley A, Banapour B, Axthelm MK, Benjamini E, Gardner MB. SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques. J Med Primatol 1993. [DOI: 10.1111/j.1600-0684.1993.tb00651.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- José V. Torres
- Department of Microbiology and ImmunologyUniversity of CaliforniaDavisCA
| | - David E. Anderson
- Department of Microbiology and ImmunologyUniversity of CaliforniaDavisCA
| | | | - Babak Banapour
- Department of PathologySchool of MedicineUniversity of CaliforniaDavisCA
| | | | - Eli Benjamini
- Department of Microbiology and ImmunologyUniversity of CaliforniaDavisCA
| | - Murray B. Gardner
- Department of PathologySchool of MedicineUniversity of CaliforniaDavisCA
| |
Collapse
|
46
|
Abstract
Different populations of wild mice (Mus musculus domesticus) in Los Angeles and Ventura Counties were observed over their lifespan in captivity for expression of infectious murine leukemia virus (MuLV) and murine mammary tumor virus (MMTV) and for the occurrence of cancer and other diseases. In most populations of feral mice these indigenous retroviruses were infrequently expressed and cancer seldom occurred until later in life (> 2 years old). MMTV was found in the milk of about 50% of wild mice, but was associated with only a low incidence (> 1%) of breast cancer after one year of age. By contrast, in several populations, most notably at a squab farm near Lake Casitas (LC), infectious MuLV acquired at birth via milk was highly prevalent, and the infected mice were prone to leukemia and a lower motor neuron paralytic disease after one year of age. These two diseases were both caused by the same infectious (ecotropic) strain of MuLV and were the principal cause of premature death in these aging LC mice. A dominant gene called FV-4R restricting the infection with ecotropic MuLV was found segregating in LC mice. Mice inheriting this FV-4R allele were resistant to the ecotropic MuLV associated lymphoma and paralysis. The FV-4R allele represents a defective endogenous MuLV provirus DNA segment that expresses an ecotropic MuLV envelope-related glycoprotein (gp70) on the cell surface. This FV-4R encoded gp70 presumably occupies the receptor for ecotropic MuLV and blocks entry of the virus. The FV-4R gene was probably acquired by the naturally occurring crossbreeding of LC feral mice with another species of feral mice (Mus castaneus) from Southeast Asia. The FV-4R gp70 does not block entry of the amphotropic MuLV that uses a separate cell surface receptor. Therefore LC mice continued to be susceptible to the highly prevalent but weakly lymphogenic and nonparalytogenic amphotropic strain of MuLV. The study points out the potential of feral populations to reveal genes associated with specific disease resistance.
Collapse
Affiliation(s)
- M B Gardner
- Department of Pathology, University of California, School of Medicine, Davis 95616
| |
Collapse
|
47
|
Yamamoto JK, Hohdatsu T, Olmsted RA, Pu R, Louie H, Zochlinski HA, Acevedo V, Johnson HM, Soulds GA, Gardner MB. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol 1993; 67:601-5. [PMID: 8380095 PMCID: PMC237403 DOI: 10.1128/jvi.67.1.601-605.1993] [Citation(s) in RCA: 87] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
More than 90% of cats immunized with inactivated whole infected-cell or cell-free feline immunodeficiency virus (FIV) vaccines were protected against intraperitoneal infection with 10 50% animal infectious doses of either homologous FIV Petaluma (28 of 30 cats) or heterologous FIV Dixon strain (27 of 28 cats). All 15 control cats were readily infected with either strain of FIV. Protection appears to correlate with antiviral envelope antibody levels by a mechanism yet to be determined.
Collapse
Affiliation(s)
- J K Yamamoto
- Department of Medicine, School of Veterinary Medicine, University of California, Davis 95616
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Giavedoni LD, Planelles V, Haigwood NL, Ahmad S, Kluge JD, Marthas ML, Gardner MB, Luciw PA, Yilma TD. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 1993; 67:577-83. [PMID: 8416384 PMCID: PMC237398 DOI: 10.1128/jvi.67.1.577-583.1993] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Simian immunodeficiency virus (SIV) infection of rhesus macaques is a model for human immunodeficiency virus (HIV) infection in humans. Inactivated and modified live whole-virus vaccines have provided limited protective immunity against SIV in rhesus macaques. Because of safety concerns in the use of inactivated and live whole-virus vaccines, we evaluated the protective immunity of vaccinia virus recombinants expressing the surface glycoprotein (gp130) of SIVmac and subunit preparations of gp130 expressed in mammalian cells (CHO). Three groups of animals were immunized with recombinant SIV gp130. The first group received SIV gp130 purified from genetically engineered CHO cells (cSIVgp130), the second group was vaccinated with recombinant vaccinia virus expressing SIVmac gp130 (vSIVgp130), and the third group was first primed with vSIVgp130 and then given a booster immunization with cSIVgp130. Although anti-gp130 binding antibodies were elicited in all three groups, neutralizing antibodies were transient or undetectable. None of the immunized animals resisted intravenous challenge with a low dose of cell-free virus. However, the group primed with vSIVgp130 and then boosted with cSIVgp130 had the lowest antigen load (p27) compared with the other groups. The results of these studies suggest that immunization of humans with HIV type 1 surface glycoprotein may not provide protective immunity against virus infection.
Collapse
Affiliation(s)
- L D Giavedoni
- Department of Veterinary Microbiology, University of California, Davis 95616
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Murphey-Corb M, Ohkawa S, Davison-Fairburn B, Martin LN, Baskin GB, Langlois AJ, McIntee M, Narayan O, Gardner MB. A formalin-fixed whole SIV vaccine induces protective responses that are cross-protective and durable. AIDS Res Hum Retroviruses 1992; 8:1475-8. [PMID: 1466986 DOI: 10.1089/aid.1992.8.1475] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Affiliation(s)
- M Murphey-Corb
- Tulane Regional Primate Research Center, Covington, LA 70434
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Giavedoni LD, Jones L, Gardner MB, Gibson HL, Ng CT, Barr PJ, Yilma T. Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A 1992; 89:3409-13. [PMID: 1565633 PMCID: PMC48877 DOI: 10.1073/pnas.89.8.3409] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
We have developed a method for attenuating vaccinia virus recombinants by expressing a fusion protein of a lymphokine and an immunogen. Chimeric genes were constructed that coded for gamma interferon (IFN-gamma) and structural proteins of the human immunodeficiency virus type 1 (HIV-1). In this study, we describe the biological and immunological properties of vaccinia virus recombinants expressing chimeric genes of murine or human IFN-gamma with glycoprotein gp120, gag, and a fragment of gp41. All fusion proteins retained the antigenic characteristics of both IFN-gamma and HIV as shown by immunoblot analysis. However, the antiviral activity of IFN-gamma could be demonstrated only for the IFN-gamma-gag fusion protein. In contrast, the attenuating activity of IFN-gamma for nude mice was retained by all of the recombinants, albeit at various rates. Unlike the antiviral activity, the attenuating activity of IFN-gamma was not species specific. Implications for the development of attenuated live recombinant vaccines for AIDS are discussed.
Collapse
Affiliation(s)
- L D Giavedoni
- Department of Veterinary Microbiology and Immunology, University of California, Davis 95616
| | | | | | | | | | | | | |
Collapse
|